| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/kura-oncology-kura-moves-83-higher-will-strength-last","as_of":"2026-04-20T13:10:00.946643+00:00","canonical_url":"https://www.nasdaq.com/articles/kura-oncology-kura-moves-83-higher-will-strength-last","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/kura-oncology-kura-moves-83-higher-will-strength-last","article_chars":3339,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_8490aeaf02e0b02f","canonical_host":"nasdaq.com","canonical_is_aggregator":false,"canonical_url":"https://www.nasdaq.com/articles/kura-oncology-kura-moves-83-higher-will-strength-last","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-20T13:21:10.182006+00:00","extraction_method":"trafilatura","fetched_description":"Kura Oncology (KURA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.","fetched_title":"Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last? | Nasdaq","final_url":"https://www.nasdaq.com/articles/kura-oncology-kura-moves-83-higher-will-strength-last","html_truncated":false,"paywall_likely":false,"publisher_domain":"nasdaq.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/kura-oncology-kura-moves-83-higher-will-strength-last","source_event_id":"evt_58eb2a196141","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"4edbb6e3e8ce73da","kind":"new_listings","published_at":"2026-04-20T11:21:00+00:00","publisher_domain":"nasdaq.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":[],"entities":[{"asset_class":"equity","name":"Kura Oncology","relevance":"high","symbol":"KURA","type":"company"},{"asset_class":"other","name":"FIT-001 study","relevance":"high","symbol":"","type":"clinical_study"},{"asset_class":"other","name":"darlifarnib","relevance":"medium","symbol":"","type":"drug"},{"asset_class":"other","name":"cabozantinib","relevance":"medium","symbol":"","type":"drug"},{"asset_class":"equity","name":"Moderna","relevance":"low","symbol":"MRNA","type":"company"}],"event_type":"price_action","information_gaps":["The article does not provide the actual trading volume figure or the \u201chigher than average\u201d volume metric.","No specific date is given for the \u201clast trading session\u201d or for the 30-day EPS revision window beyond \u201cover the last 30 days.\u201d","The article does not quantify the \u201cstrong anti-tumor activity\u201d or \u201cmanageable safety profile\u201d (e.g., response rates, adverse event rates).","The article does not specify the exact timing/date of the upcoming report.","The article includes general commentary about correlations between earnings estimate revisions and near-term stock price movements, but does not provide supporting data within the text."],"key_facts":["KURA shares rallied 8.3% in the last trading session to close at $9.68.","The article attributes the move to notable trading volume (more shares traded than a typical session).","KURA had gained 6.1% over the past four weeks (per the article).","The rally followed an announcement of encouraging preliminary data from the ongoing FIT-001 study evaluating darlifarnib plus cabozantinib in previously treated clear cell renal cell carcinoma (ccRCC) patients.","The treatment showed strong anti-tumor activity and a manageable safety profile across different dose levels, including full-dose cabozantinib (as stated).","The study has progressed to the phase Ib dose-expansion stage to identify the most effective and biologically active dose for the combination.","The upcoming report is expected to show quarterly loss of $0.89 per share, a year-over-year change of -34.9% (as stated).","Revenues are expected to be $15.06 million, up 6.7% year over year (as stated).","Consensus EPS estimate for the quarter was revised 2.8% lower over the last 30 days to the current level (as stated).","The stock carries a Zacks Rank #3 (Hold) (as stated).","The article states that negative earnings estimate revision trends do not usually translate into price appreciation (general statement within the article)."],"numeric_claims":[{"label":"Price change (last session)","value":"8.3%"},{"label":"Close price","value":"$9.68"},{"label":"Gain over past four weeks","value":"6.1%"},{"label":"Expected quarterly loss per share","value":"-$0.89"},{"label":"YoY change in expected EPS","value":"-34.9%"},{"label":"Expected revenues","value":"$15.06 million"},{"label":"YoY revenue growth","value":"6.7%"},{"label":"EPS estimate revision (last 30 days)","value":"-2.8%"}],"primary_claim":"Kura Oncology (KURA) shares rallied 8.3% to close at $9.68 after the company announced encouraging preliminary FIT-001 study data.","relevance_score":0.72,"sentiment":"mixed","source_quality":"high","summary":"Kura Oncology\u2019s shares rose 8.3% in the last trading session to close at $9.68, following encouraging preliminary data from its FIT-001 study. The article notes that recent earnings estimate revisions have moved slightly lower, which may limit additional near-term upside.","topics":["stock price move","trading volume","clinical trial preliminary data","earnings estimate revisions","Zacks Rank","renal cell carcinoma (ccRCC)"]},"source":"Nasdaq Stocks","source_domain":"nasdaq.com","summary":"Kura Oncology (KURA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.","tickers":["KURA"],"title":"Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?","url":"https://www.nasdaq.com/articles/kura-oncology-kura-moves-83-higher-will-strength-last"}... |